Mirum Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
Mirum Pharmaceuticals, Inc. (MIRM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2020-03-12
- Mirum Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-12-31 was $0.00.
- Mirum Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-09-30 was $0.00.
- Mirum Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |